🔎 Trials Near Me

Utama › Leukemia Mieloid Akut › Alabama › Birmingham

Kajian klinikal Leukemia Mieloid Akut di Birmingham, AL

21 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi dalam dan sekitar Birmingham (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Mengambil pesertaFasa 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Umur 18 hingga 59 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Mengambil pesertaFasa 3
  • University of Alabama at Birmingham, Birmingham
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Mengambil pesertaFasa 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Mengambil pesertaFasa 1
  • Children's Hospital of Alabama, Birmingham
Sehingga umur 21 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Mengambil pesertaFasa 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Mengambil pesertaFasa 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Umur 18 hingga 59 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Mengambil pesertaFasa 3
  • Children's Hospital of Alabama, Birmingham
6 Months – 21 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Mengambil pesertaFasa 2
  • University of Alabama - Birmingham, Birmingham
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06824168

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Mengambil pesertaFasa 3
  • Children's Hospital of Alabama, Birmingham
Umur 1 hingga 25 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Mengambil pesertaFasa 1/2
  • O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Umur 12 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT04588922

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Mengambil pesertaFasa 2/3
  • University of Alabama Birmingham, Birmingham
Umur 18 hingga 80 · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06788756

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Mengambil pesertaKajian pemerhatian
  • University of Alabama at Birmingham, Birmingham
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Mengambil peserta
  • University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
Umur 60 ke atas · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06697600

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Mengambil pesertaFasa 1
  • University of Alabama at Birmingham, Birmingham
Umur 18 hingga 75 · Semua jantina · Dikemas kini 4 Mac 2026 · NCT07044544

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Mengambil pesertaFasa 1
  • University of Alabama O'Neal Cancer Center, Birmingham
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jan 2026 · NCT05143996

HPC Offered for PRESERVE Expansion

Mengambil pesertaKajian pemerhatian
  • University of Alabama, Birmingham, Birmingham
Umur 12 hingga 80 · Semua jantina · Dikemas kini 28 Ogo 2025 · NCT07145411

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Mengambil pesertaFasa 1/2
  • The Kirklin Clinic of UAB Hospital, Birmingham
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Mengambil pesertaSukarelawan sihat dialu-alukan
  • University of Alabama - Birmingham, Birmingham
Umur 18 hingga 120 · Semua jantina · Dikemas kini 25 Jul 2025 · NCT05237258

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Mengambil pesertaFasa 1
  • University of Alabama at Birmingham, Birmingham
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Nov 2024 · NCT06034275

Kajian Leukemia Mieloid Akut di bandar lain

Kajian lain di Birmingham

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.